These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8993499)

  • 1. Mechanism of action of camptothecin.
    Liu LF; Duann P; Lin CT; D'Arpa P; Wu J
    Ann N Y Acad Sci; 1996 Dec; 803():44-9. PubMed ID: 8993499
    [No Abstract]   [Full Text] [Related]  

  • 2. Ubiquitin, SUMO-1, and UCRP in camptothecin sensitivity and resistance.
    Desai SD; Mao Y; Sun M; Li TK; Wu J; Liu LF
    Ann N Y Acad Sci; 2000; 922():306-8. PubMed ID: 11193908
    [No Abstract]   [Full Text] [Related]  

  • 3. Using yeast to understand drugs that target topoisomerases.
    Nitiss JL; Rose A; Sykes KC; Harris J; Zhou J
    Ann N Y Acad Sci; 1996 Dec; 803():32-43. PubMed ID: 8993498
    [No Abstract]   [Full Text] [Related]  

  • 4. Cellular resistance to camptothecins.
    Pommier Y; Gupta M; Valenti M; Nieves-Neira W
    Ann N Y Acad Sci; 1996 Dec; 803():60-73. PubMed ID: 8993501
    [No Abstract]   [Full Text] [Related]  

  • 5. Camptothecin resistance related to drug-induced down-regulation of topoisomerase I and to steps occurring after the formation of protein-linked DNA breaks.
    Murren JR; Beidler DR; Cheng YC
    Ann N Y Acad Sci; 1996 Dec; 803():74-92. PubMed ID: 8993502
    [No Abstract]   [Full Text] [Related]  

  • 6. Structure-based analysis of the effects of camptothecin on the activities of human topoisomerase I.
    Champoux JJ
    Ann N Y Acad Sci; 2000; 922():56-64. PubMed ID: 11193925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of topoisomerase I mutations affecting both DNA cleavage and interaction with camptothecin.
    Li XG; Haluska P; Hsiang YH; Bharti A; Kufe DW; Rubin EH
    Ann N Y Acad Sci; 1996 Dec; 803():111-27. PubMed ID: 8993505
    [No Abstract]   [Full Text] [Related]  

  • 8. Mechanisms of resistance to camptothecins.
    Saleem A; Edwards TK; Rasheed Z; Rubin EH
    Ann N Y Acad Sci; 2000; 922():46-55. PubMed ID: 11193924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulation of DNA replication in extracts of camptothecin-treated cells: activation of an S-phase checkpoint?
    Wang Y; Perrault AR; Iliakis G
    Cancer Res; 1997 May; 57(9):1654-9. PubMed ID: 9135002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complex response of breast epithelial cell lines to topoisomerase inhibitors.
    Davis PL; Shaiu WL; Scott GL; Iglehart JD; Hsieh TS; Marks JR
    Anticancer Res; 1998; 18(4C):2919-32. PubMed ID: 9713486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Luotonin A. A naturally occurring human DNA topoisomerase I poison.
    Cagir A; Jones SH; Gao R; Eisenhauer BM; Hecht SM
    J Am Chem Soc; 2003 Nov; 125(45):13628-9. PubMed ID: 14599178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lowered phosphorylation of topoisomerase I is a direct reason for reduced sensitivity of L5178Y-S cells to camptothecin.
    Staron K; Kowalska-Loth B; Szumiel I
    Ann N Y Acad Sci; 1996 Dec; 803():321-3. PubMed ID: 8993529
    [No Abstract]   [Full Text] [Related]  

  • 13. Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?
    Jung LL; Zamboni WC
    Drug Resist Updat; 2001 Aug; 4(4):273-88. PubMed ID: 11998845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A structural model for the ternary cleavable complex formed between human topoisomerase I, DNA, and camptothecin.
    Kerrigan JE; Pilch DS
    Biochemistry; 2001 Aug; 40(33):9792-8. PubMed ID: 11502172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity.
    Morris EJ; Geller HM
    J Cell Biol; 1996 Aug; 134(3):757-70. PubMed ID: 8707853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin.
    Chang JY; Liu JF; Juang SH; Liu TW; Chen LT
    Cancer Res; 2002 Jul; 62(13):3716-21. PubMed ID: 12097280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic proteomics of individual cancer cells in response to a drug.
    Cohen AA; Geva-Zatorsky N; Eden E; Frenkel-Morgenstern M; Issaeva I; Sigal A; Milo R; Cohen-Saidon C; Liron Y; Kam Z; Cohen L; Danon T; Perzov N; Alon U
    Science; 2008 Dec; 322(5907):1511-6. PubMed ID: 19023046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives.
    Chen AY; Okunieff P; Pommier Y; Mitchell JB
    Cancer Res; 1997 Apr; 57(8):1529-36. PubMed ID: 9108456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA topoisomerase I-targeting drugs as radiation sensitizers.
    Chen AY; Choy H; Rothenberg ML
    Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):39-46. PubMed ID: 10550825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
    Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.